ReviewBiochemistry and biophysics reports2025
The structure and function of FBXW5 in human diseases.
Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FBXW5, a member of the F-box protein family, plays a pivotal role in various cellular processes through its involvement in ubiquitin-mediated proteolysis as a component of the SCF complex. Recent studies have highlighted the potential of targeting FBXW5 for therapeutic interventions, making it a promising candidate for drug development. Thus, it is of great importance to provide a comprehensive overview of the structure and function of FBXW5, with a particular focus on its binding motifs for gene regulation and activities to recruitment and recognition. Herein, this review summarizes the biological significance of FBXW5 in different diseases, including cancers, neurological disorders, and other pathological conditions. This review also discusses the current challenges and future perspectives in research on FBXW5 in human diseases. Although direct inhibitors are lacking, therapeutic vulnerability is achieved via SCF inhibition or targeting hyperactivated downstream signaling nodes, emphasizing the need for further studies to fully elucidate its biological functions and therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.